Vivus jumps on FDA request to remove contraindication in proposed Qnexa label
This article was originally published in Scrip
Executive Summary
Investors welcomed the news that the US FDA asked Vivus to remove the contraindication for women of childbearing potential from the proposed labelling of the company's experimental weight-loss pill Qnexa (phentermine/topiramate), with shares climbing as high as 17.1%.